Analysts Offer Insights on Healthcare Companies: Regeneron (NASDAQ: REGN), SurModics (NASDAQ: SRDX) and Retrophin (NASDAQ: RTRX)

By Ryan Adsit

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Regeneron (NASDAQ: REGN), SurModics (NASDAQ: SRDX) and Retrophin (NASDAQ: RTRX).

Regeneron (NASDAQ: REGN)

In a report released today, Biren Amin from Jefferies reiterated a Hold rating on Regeneron (NASDAQ: REGN), with a price target of $394. The company’s shares opened today at $406.14.

Amin said:

“This morning, REGN announced the Data Monitoring Committee for the ODYSSEY OUTCOMES trial recommended the trial continue to final completion as the bar to stop the study on overwhelming efficacy was not met. REGN had guided the interim bar was high and would need to meet several criteria in addition to overwhelming CV outcome reduction over the control group.”

According to TipRanks.com, Amin is a 4-star analyst with an average return of 6.0% and a 54.1% success rate. Amin covers the Healthcare sector, focusing on stocks such as Bellicum Pharmaceuticals, Anthera Pharmaceuticals, and Aquinox Pharmaceuticals.

Currently, the analyst consensus on Regeneron is Hold and the average price target is $434.60, representing a 7.0% upside.

In a report issued on November 4, Canaccord Genuity also reiterated a Hold rating on the stock with a $450 price target.
SurModics (NASDAQ: SRDX)

In a report released today, Jan Wald from Benchmark Co. reiterated a Buy rating on SurModics (NASDAQ: SRDX), with a price target of $30. The company’s shares opened today at $25.65.

According to TipRanks.com, Wald is a 4-star analyst with an average return of 13.0% and a 61.9% success rate. Wald covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp., Cardiovascular Systems, and Staar Surgical Company.

SurModics has an analyst consensus of Moderate Buy, with a price target consensus of $30.

Retrophin (NASDAQ: RTRX)

BMO Capital analyst Do Kim reiterated a Buy rating on Retrophin (NASDAQ: RTRX) yesterday and set a price target of $40. The company’s shares opened today at $21.31.

According to TipRanks.com, Kim is a 5-star analyst with an average return of 23.1% and a 75.0% success rate. Kim covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Cynapsus Therapeutics, and Fate Therapeutics.

Currently, the analyst consensus on Retrophin is Strong Buy and the average price target is $40, representing an 87.7% upside.

In a report issued on November 4, JMP Securities also reiterated a Buy rating on the stock.